StockNews.com Begins Coverage on Global Cord Blood (NYSE:CO)

Analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a report released on Friday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of CO stock opened at $1.30 on Friday. The company has a market capitalization of $158.02 million, a P/E ratio of 2.03 and a beta of 0.16. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The company’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.36.

Hedge Funds Weigh In On Global Cord Blood

Several hedge funds and other institutional investors have recently made changes to their positions in CO. Northern Trust Corp acquired a new stake in Global Cord Blood during the 2nd quarter valued at $96,000. Natixis Advisors L.P. lifted its holdings in Global Cord Blood by 5.6% during the 2nd quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock valued at $592,000 after purchasing an additional 10,550 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC lifted its holdings in Global Cord Blood by 99,844.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after purchasing an additional 26,067,412 shares during the last quarter.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.